Iduronate 2 Sulfatase - Drugs In Development, 2021
Iduronate 2 Sulfatase - Drugs In Development, 2021
SUMMARY
According to the recently published report 'Iduronate 2 Sulfatase - Drugs In Development, 2021'; Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.
The report 'Iduronate 2 Sulfatase - Drugs In Development, 2021' outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Iduronate 2 Sulfatase - Drugs In Development, 2021'; Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.
The report 'Iduronate 2 Sulfatase - Drugs In Development, 2021' outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
- The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Companies Involved in Therapeutics Development
AVROBIO Inc
Bioasis Technologies Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Homology Medicines Inc
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Takeda Pharmaceutical Co Ltd
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Drug Profiles
AVRRD-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pabinafusp alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Dormant Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Discontinued Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Product Development Milestones
Featured News & Press Releases
May 14, 2021: REGENXBIO presents additional positive interim data from phase I/II trial of RGX-121 for the treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting
Apr 14, 2021: Regenxbio announces dosing of first patient in cohort 3 of phase I/II trial of RGX-121 for the treatment of MPS II (Hunter syndrome)
Mar 23, 2021: JCR Pharmaceuticals announces approval of IZCARGO (pabinafusp alfa) for treatment of MPS II (Hunter syndrome) in Japan
Mar 11, 2021: Denali Therapeutics announces fast track designation granted by the U.S. FDA to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II)
Mar 03, 2021: GC Green Cross to ship'Hunterase ICV' in Japan
Feb 16, 2021: JCR Pharmaceuticals presents research at WORLDSymposium 2021 showing potential benefits of JR-141 (pabinafusp alfa) in patients with MPS II (Hunter Syndrome)
Feb 12, 2021: Denali Therapeutics reports positive three-month data from phase 1/2 study with ETV:IDS (DNL310) in patients with hunter syndrome (MPS II)
Feb 10, 2021: JCR Pharmaceuticals receives FDA IND clearance to initiate global phase 3 clinical trial of JR-141 for Mucopolysaccharidosis Type II (Hunter Syndrome)
Feb 10, 2021: FDA grants fast track designation for JR-141 for the treatment of mucopolysaccharidosis type II (Hunter syndrome)
Feb 08, 2021: Homology Medicines announces first presentation of data with HMI-203 in vivo gene therapy development candidate for Hunter syndrome
Feb 08, 2021: Regenxbio presents additional positive interim data from Phase I/II Trial Of Rgx-121 For The Treatment Of MPS II (Hunter Syndrome) at 17th Annual Worldsymposium 2021
Feb 05, 2021: Denali Therapeutics to present new data on ETV:IDS (DNL310) for the potential treatment of Hunter syndrome at WORLDSymposium
Jan 27, 2021: JR-141 (Pabinafusp Alfa) for Hunter syndrome: Notice on the publication of the results of non-clinical trials in Molecular Therapy
Jan 22, 2021: Announcing marketing approval for Hunterase ICV Injection 15 mg, the world’s first enzyme replacement therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) administered by ICV injection
Dec 23, 2020: JCR files Hunter Syndrome drug in Brazil
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Companies Involved in Therapeutics Development
AVROBIO Inc
Bioasis Technologies Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Homology Medicines Inc
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Takeda Pharmaceutical Co Ltd
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Drug Profiles
AVRRD-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pabinafusp alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Dormant Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Discontinued Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Product Development Milestones
Featured News & Press Releases
May 14, 2021: REGENXBIO presents additional positive interim data from phase I/II trial of RGX-121 for the treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting
Apr 14, 2021: Regenxbio announces dosing of first patient in cohort 3 of phase I/II trial of RGX-121 for the treatment of MPS II (Hunter syndrome)
Mar 23, 2021: JCR Pharmaceuticals announces approval of IZCARGO (pabinafusp alfa) for treatment of MPS II (Hunter syndrome) in Japan
Mar 11, 2021: Denali Therapeutics announces fast track designation granted by the U.S. FDA to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II)
Mar 03, 2021: GC Green Cross to ship'Hunterase ICV' in Japan
Feb 16, 2021: JCR Pharmaceuticals presents research at WORLDSymposium 2021 showing potential benefits of JR-141 (pabinafusp alfa) in patients with MPS II (Hunter Syndrome)
Feb 12, 2021: Denali Therapeutics reports positive three-month data from phase 1/2 study with ETV:IDS (DNL310) in patients with hunter syndrome (MPS II)
Feb 10, 2021: JCR Pharmaceuticals receives FDA IND clearance to initiate global phase 3 clinical trial of JR-141 for Mucopolysaccharidosis Type II (Hunter Syndrome)
Feb 10, 2021: FDA grants fast track designation for JR-141 for the treatment of mucopolysaccharidosis type II (Hunter syndrome)
Feb 08, 2021: Homology Medicines announces first presentation of data with HMI-203 in vivo gene therapy development candidate for Hunter syndrome
Feb 08, 2021: Regenxbio presents additional positive interim data from Phase I/II Trial Of Rgx-121 For The Treatment Of MPS II (Hunter Syndrome) at 17th Annual Worldsymposium 2021
Feb 05, 2021: Denali Therapeutics to present new data on ETV:IDS (DNL310) for the potential treatment of Hunter syndrome at WORLDSymposium
Jan 27, 2021: JR-141 (Pabinafusp Alfa) for Hunter syndrome: Notice on the publication of the results of non-clinical trials in Molecular Therapy
Jan 22, 2021: Announcing marketing approval for Hunterase ICV Injection 15 mg, the world’s first enzyme replacement therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) administered by ICV injection
Dec 23, 2020: JCR files Hunter Syndrome drug in Brazil
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AVROBIO Inc, 2021
Pipeline by Bioasis Technologies Inc, 2021
Pipeline by Denali Therapeutics Inc, 2021
Pipeline by Esteve Pharmaceuticals SA, 2021
Pipeline by GC Pharma, 2021
Pipeline by Homology Medicines Inc, 2021
Pipeline by JCR Pharmaceuticals Co Ltd, 2021
Pipeline by RegenxBio Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AVROBIO Inc, 2021
Pipeline by Bioasis Technologies Inc, 2021
Pipeline by Denali Therapeutics Inc, 2021
Pipeline by Esteve Pharmaceuticals SA, 2021
Pipeline by GC Pharma, 2021
Pipeline by Homology Medicines Inc, 2021
Pipeline by JCR Pharmaceuticals Co Ltd, 2021
Pipeline by RegenxBio Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
